Flow cytometric analysis of human PBMC (human peripheral blood mononuclear cell) labelling Human CD3ε antibody at 1/2000 (0.1 μg) dilution (Right) compared with a Mouse monoclonal IgG isotype control (Left). Goat Anti - Mouse IgG Alexa Fluor® 488 was used as the secondary antibody. Then cells were stained with CD19 - Brilliant Violet 421™ separately. Events were gated on viable lymphocytes.
Product Details
Product Details
Product Specification
Host | Mouse |
Antigen | CD3 |
Synonyms | T-cell surface antigen T3/Leu-4 epsilon chain; CD3e; T3E |
Location | Cell membrane |
Accession | P07766 |
Clone Number | S-R531 |
Antibody Type | Mouse mAb |
Isotype | IgG2a |
Application | FCM |
Reactivity | Hu |
Positive Sample | human PBMC |
Predicted Reactivity | Gor, Pr, Cz, Or, Bv, Sh, Rt, Ct, Rb, Dg, De, Hdg, Bb, Hr, Ms |
Purification | Protein A |
Concentration | 2 mg/ml |
Conjugation | Unconjugated |
Physical Appearance | Liquid |
Storage Buffer | PBS pH7.4 |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
application | dilution | species |
FCM | 1:2000 | Hu |
Background
CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). It is composed of four distinct chains. In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. These chains associate with the T-cell receptor (TCR) and the CD3-zeta (ζ-chain) to generate an activation signal in T lymphocytes. The TCR, CD3-zeta, and the other CD3 molecules together constitute the TCR complex. The CD3–T cell receptor (TCR) complex plays a central role in the T-cell-mediated immunoresponse as it is involved in the recognition of antigens and subsequent signal transduction and activation of immunocompetent T lymphocytes. Because CD3 is required for T cell activation, drugs (often monoclonal antibodies) that target it are being investigated as immunosuppressant therapies (e.g., otelixizumab, teplizumab) for type 1 diabetes and other autoimmune diseases.
Picture
Picture
FC
